IP Library Granted Patent US 12,186,547
Granted Patent B2
US 12,186,547 · App. 17/389,551 · Granted Jan 7, 2025

Peripheral nerve stimulation for Restless Legs Syndrome

Inventors: Jonathan David Charlesworth (San Francisco, CA); Shriram Raghunathan (Castro Valley, CA)
Assignee: NOCTRIX HEALTH, INC.
A61N1/0452A61N1/0456A61N1/0492
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,547
App. No.
17/389,551
Granted
Jan 7, 2025
Kind
B2
Abstract

Systems and methods for treating a patient having symptoms of restless legs syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) using high-frequency stimulation by applying a high-frequency pulsed electrostimulation therapy signal to a peroneal nerve or a branch thereof, where the therapy signal is above a motor threshold of a muscle innervated by the peroneal nerve or branch thereof. Surface EMG (sEMG) response to neurostimulation can be used to evaluate patient responsivity to neurostimulation, or to evaluate neurostimulation efficacy, such as to compare various neurostimulation parameter settings and to select between such settings to meet or balance between one or more goals. The sEMG response can be obtained with the muscle at rest, or during muscle activation.

Claims (33)

1. A system for treating a patient having one or more symptoms associated with at least one of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) using applied high-frequency electrostimulation, the system comprising:

at least one electrostimulation electrode configured for location at a first external target body location on a leg near a target nerve or a branch thereof; and

a wearable external, non-implantable electrostimulation unit coupled to the at least one electrostimulation electrode for generating and applying to the target nerve or branch thereof a first high-frequency electrostimulation signal, having a frequency within a range of 2 kilohertz (kHz) and 6 kHz and controlled such that, when the at least one electrostimulation electrode is in place over the head of a patient fibula, signal induces tonic motor activation of a tibialis anterior muscle in response to a specified current intensity within a range of 15 milliamps (mA) and 40 mA; and

onboard power management circuitry coupled to the electrostimulation unit for powering the electrostimulation unit via a battery.

2. The system of claim 1 , wherein the electrostimulation unit is configured for generating and applying the first high-frequency electrostimulation signal to produce tonic sEMG activity in response to the electrostimulation signal.

3. The system of claim 1 , wherein the electrostimulation unit is configured for generating and applying the first high-frequency electrostimulation signal to modulate phasic sEMG activity in response to the electrostimulation signal.

4. The system of claim 1 , wherein at least one parameter setting of the first high-frequency electrostimulation signal is specified for treating the at least one of RLS or PLMD, based at least in part on an observed surface electromyographic (sEMG) signal.

5. The system of claim 1 , wherein at least one parameter setting of first high-frequency electrostimulation signal is specified for treating the at least one of RLS or PLMD, based at least in part on patient feedback, to be less than at least one of a pain threshold or a distraction threshold.

6. The system of claim 1 , wherein at least one parameter setting of the first high-frequency electrostimulation signal is configured for treating the at least one of RLS or PLMD to permit being specified differently based on a time-of-day or other indication of whether the patient is, or is expected to be, one of awake or asleep.

7. The system of claim 1 , wherein the electrostimulation unit includes or is coupled to controller circuitry configured to determine whether, or a degree to which, the first high-frequency electrostimulation signal produces tonic sEMG activity in an observed sEMG signal from the same patient for providing an indicator of efficacy of electrostimulation treatment of at least one of RLS or PLMD.

8. The system of claim 1 , wherein the electrostimulation unit includes or is coupled to controller circuitry that is configured to store indications of sEMG activity respectively corresponding to different settings of at least one parameter of the first high-frequency electrostimulation signal for treating at least one of RLS or PLMD.

9. The system of claim 1 , wherein the electrostimulation unit includes or is coupled to controller circuitry that is configured to select at least one parameter setting for treating at least one of RLS or PLMD of the first high-frequency electrostimulation signal based on a comparison of sEMG activity at different settings.

10. The system of claim 9 , wherein the controller circuitry is configured to characterize a neurostimulation responsiveness for treating at least one of RLS or PLMD based at least in part on at least one of a tonic motor activation threshold, a distraction threshold, or a pain threshold, determined using one or more parameter settings of the first high-frequency electrostimulation signal.

11. The system of claim 1 , wherein the electrostimulation unit includes or is coupled to controller circuitry that is configured to record an indication of baseline sEMG activity obtained without providing the first high-frequency electrostimulation signal to the patient.

12. The system of claim 11 , wherein the controller circuitry is configured to characterize a neurostimulation responsiveness for treating at least one of RLS or PLMD of the patient based at least in part on a change in observed sEMG activity in the patient from the baseline sEMG activity, in response to the first high-frequency electrostimulation signal.

13. The system of claim 1 , further comprising at least one sEMG signal electrode configured to be located in association with at least one muscle innervated by the target nerve of the same patient to which the first high-frequency electrostimulation signal is delivered by the at least one electrostimulation electrode for treating at least one of RLS or PLMD.

14. The system of claim 1 , wherein the at least one electrostimulation electrode locatable at a first external target body location on a leg near a target nerve or a branch thereof comprises:

at least one first electrostimulation electrode configured for location at a first external target body location on a right leg of the patient near a right target nerve or a branch thereof; and

at least one second electrostimulation electrode configured for location at a second external target body location on a left leg of the patient near a left target nerve or a branch thereof;

wherein the electrostimulation unit generates the first high-frequency electrostimulation signal for delivery to the right target nerve or branch thereof for treating at least one of RLS or PLMD using the at least one first electrostimulation electrode to produce or modulate tonic surface electromyographic (sEMG) activity in at least one muscle innervated by the right target nerve and generates a second high-frequency pulsed electrostimulation signal for delivery to the left target nerve or branch thereof using the at least one second electrostimulation electrode to produce or modulate tonic surface electromyographic (sEMG) activity in at least one muscle innervated by the left target nerve.

15. The system of claim 1 , wherein the electrostimulation unit is configured to repeatedly deliver pulses of the first high-frequency electrostimulation signal for treating at least one of RLS or PLMD in a ramped manner of increasing energy levels toward a target energy level.

16. The system of claim 1 , comprising an arrangement of a plurality of electrodes, wherein the electrostimulation unit includes or is coupled to controller circuitry that is configured to select one or more electrodes from the plurality of electrodes based at least in part on observed sEMG activity indicative of at least one of RLS or PLMD treatment efficacy in response to a test electrostimulation signal delivered to the patient via different ones of the plurality of electrodes, and use the selected one or more electrodes to apply a therapeutic electrostimulation signal to the patient.

17. The system of claim 1 , wherein the electrostimulation unit includes or is coupled to controller circuitry configured for specifying at least one parameter setting of the first high-frequency electrostimulation signal for treating at least one of RLS or PLMD, based at least in part on a modulation of phasic sEMG activity in an observed sEMG signal together with muscle activation of the at least one muscle innervated by the target nerve.

18. The system of claim 1 , wherein the electrostimulation unit is coupled to the at least one electrostimulation electrode for both delivering the first high-frequency pulsed electrostimulation signal to the patient for treating at least one of RLS or PLMD and for detecting a responsive sEMG signal from the patient, for indicating efficacy of treating at least one of RLS or PLMD, using the same at least one electrostimulation electrode.

19. A system for treating a patient having one or more symptoms associated with at least one of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) using applied high-frequency electrostimulation, the system comprising:

at least one electrostimulation electrode configured for location at a first external target body location on a leg near a target nerve or a branch thereof; and

an external, non-implantable electrostimulation unit coupled to the at least one electrostimulation electrode for generating and applying to the target nerve or branch thereof a first high-frequency electrostimulation signal, having a frequency within a range of 2 kHz to 6 kHz at a substantially 100% duty cycle during a specified electrostimulation period for producing tonic sEMG activity in at least one muscle innervated by a peroneal nerve of the patient and using at least one observed sEMG signal as an indicator of efficacy of electrostimulation treatment of the at least one of RLS or PLMD.

20. The system of claim 19 , wherein the electrostimulation unit is configured to generate and apply the first high-frequency electrostimulation signal for modulating phasic sEMG activity, including reducing or minimizing phasic sEMG activity.

21. A system for treating a patient having one or more symptoms associated with at least one of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) using applied high-frequency electrostimulation, the system comprising:

at least one electrostimulation electrode configured for location at a first external target body location on a leg near a target nerve or a branch thereof; and

a wearable external, non-implantable electrostimulation unit coupled to the at least one electrostimulation electrode for generating and applying to the target nerve or branch thereof a first high-frequency electrostimulation signal, having signal parameters including a frequency of about 4000 hertz (Hz), a pulse width of about 125 microseconds (μs), and a maximum current amplitude between 15 milliamps (mA) and 40 mA, thereby establishing a root means squared (RMS) current greater than 15 mA; and

onboard power management circuitry coupled to the electrostimulation unit for powering the electrostimulation unit via a battery.

22. The system of claim 21 , wherein the electrostimulation unit comprises controller circuitry to establish or adjust at least one parameter signal parameter of the electrostimulation signal to produce tonic motor activation of a tibialis anterior muscle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2022
From: CHARLESWORTH, JONATHAN DAVID; RAGHUNATHAN, SHRIRAM
To: NOCTRIX HEALTH, INC.
Reel/Frame 058706/0104 →
Continuity (4)
Continuation 17062010 · Oct 2, 2020
Provisional Application 62706525 · Aug 22, 2020
Provisional Application 62910241 · Oct 3, 2019
Related Publication 20220088372A1 · Mar 24, 2022
References Cited (134)
US 5487759A · Bastyr et al. · 1996 [cited by applicant]
US 5725471A · Davey et al. · 1998 [cited by applicant]
US 5759198A · Karell · 1998 [cited by applicant]
US 5995873A · Rhodes · 1999 [cited by applicant]
US 6001861A · Oertel et al. · 1999 [cited by applicant]
US 6114326A · Schueler · 2000 [cited by applicant]
US 6507757B1 · Swain · 2003 [cited by applicant]
US 6602868B2 · McBrinn et al. · 2003 [cited by applicant]
US 6958048B2 · Bonutti · 2005 [cited by applicant]
US 7403821B2 · Haugland et al. · 2008 [cited by applicant]
US 7774068B1 · Lozano · 2010 [cited by applicant]
US 7783348B2 · Gill et al. · 2010 [cited by applicant]
US 8145317B2 · Demarais et al. · 2012 [cited by applicant]
US 8365741B2 · Hennings et al. · 2013 [cited by applicant]
US 8938303B1 · Matsen · 2015 [cited by applicant]
US 8983617B2 · Chavan et al. · 2015 [cited by applicant]
US 9002477B2 · Burnett · 2015 [cited by applicant]
US 9017273B2 · Burbank et al. · 2015 [cited by applicant]
US 9205264B2 · Heruth et al. · 2015 [cited by applicant]
US 9302046B1 · Giuffrida et al. · 2016 [cited by applicant]
US 9327121B2 · Thacker et al. · 2016 [cited by applicant]
US 9387338B2 · Burnett · 2016 [cited by applicant]
US 9452287B2 · Rosenbluth et al. · 2016 [cited by applicant]
US 9474898B2 · Gozani et al. · 2016 [cited by applicant]
US 9504827B2 · DeGiorgio et al. · 2016 [cited by applicant]
US 9561371B2 · Elborno · 2017 [cited by applicant]
US 9566470B2 · Malizia · 2017 [cited by applicant]
US 9604056B2 · Starr et al. · 2017 [cited by applicant]
US 9610448B2 · Hou et al. · 2017 [cited by applicant]
US 9656070B2 · Gozani et al. · 2017 [cited by applicant]
US 9662491B2 · Yonce et al. · 2017 [cited by applicant]
US 9662502B2 · Giuffrida et al. · 2017 [cited by applicant]
US 9694181B2 · Bhadra et al. · 2017 [cited by applicant]
US 9713711B2 · Hershey et al. · 2017 [cited by applicant]
US 9737709B2 · Bachinski et al. · 2017 [cited by applicant]
US 9750933B2 · Gregory et al. · 2017 [cited by applicant]
US 9802039B2 · Palermo et al. · 2017 [cited by applicant]
US 9802041B2 · Wong et al. · 2017 [cited by applicant]
US 9808620B2 · Kent · 2017 [cited by applicant]
US 9808627B2 · Gliner et al. · 2017 [cited by applicant]
US 9814880B2 · Hershey et al. · 2017 [cited by applicant]
US 10195425B2 · Ostroff et al. · 2019 [cited by applicant]
US 10342977B2 · Raghunathan · 2019 [cited by applicant]
US 11103691B2 · Charlesworth et al. · 2021 [cited by applicant]
US 11266836B2 · Charlesworth et al. · 2022 [cited by applicant]
US 20030176822A1 · Morgenlander · 2003 [cited by applicant]
US 20040093093A1 · Andrews · 2004 [cited by applicant]
US 20060069415A1 · Cameron et al. · 2006 [cited by applicant]
US 20060173074A1 · Ellmen et al. · 2006 [cited by applicant]
US 20080262053A1 · Reess · 2008 [cited by applicant]
US 20090062685A1 · Bergethon et al. · 2009 [cited by applicant]
US 20090221943A1 · Burbank et al. · 2009 [cited by applicant]
US 20100049111A1 · Sorg · 2010 [cited by applicant]
US 20100160712A1 · Burnett et al. · 2010 [cited by applicant]
US 20100191311A1 · Scheiner et al. · 2010 [cited by applicant]
US 20100249637A1 · Walter et al. · 2010 [cited by applicant]
US 20110054573A1 · Mitchell · 2011 [cited by applicant]
US 20120101358A1 · Boettcher et al. · 2012 [cited by applicant]
US 20130245486A1 · Simon et al. · 2013 [cited by applicant]
US 20130325084A1 · Lee · 2013 [cited by applicant]
US 20140046423A1 · Rajguru et al. · 2014 [cited by applicant]
US 20140148725A1 · Cadwell · 2014 [cited by examiner]
US 20140277220A1 · Brennan et al. · 2014 [cited by applicant]
US 20150066105A1 · Elborno · 2015 [cited by applicant]
US 20150165202A1 · Grandhe · 2015 [cited by applicant]
US 20150174002A1 · Burbank et al. · 2015 [cited by applicant]
US 20150272815A1 · Kitchens · 2015 [cited by applicant]
US 20150321000A1 · Rosenbluth et al. · 2015 [cited by applicant]
US 20160030280A1 · Jones · 2016 [cited by applicant]
US 20160106344A1 · Nazari · 2016 [cited by examiner]
US 20160158542A1 · Ahmed · 2016 [cited by applicant]
US 20160310741A1 · Baru et al. · 2016 [cited by applicant]
US 20160354604A1 · Kent · 2016 [cited by applicant]
US 20170157398A1 · Wong et al. · 2017 [cited by applicant]
US 20170157404A1 · Moffitt et al. · 2017 [cited by applicant]
US 20170216586A1 · Kent · 2017 [cited by applicant]
US 20170266443A1 · Rajguru et al. · 2017 [cited by applicant]
US 20180098046A1 · Husak et al. · 2018 [cited by applicant]
US 20190001129A1 · Rosenbluth · 2019 [cited by examiner]
US 20190083784A1 · Raghunathan · 2019 [cited by applicant]
US 20200108251A1 · Raghunathan · 2020 [cited by applicant]
US 20210100998A1 · Charlesworth et al. · 2021 [cited by applicant]
US 20210260379A1 · Charlesworth et al. · 2021 [cited by applicant]
US 20220143393A1 · Charlesworth et al. · 2022 [cited by applicant]
US 20220218993A1 · Charlesworth et al. · 2022 [cited by applicant]
CN 110603073 · 2019 [cited by applicant]
CN 115087482 · 2022 [cited by applicant]
JP 2010246745A · 2010 [cited by applicant]
JP 2017503537A · 2017 [cited by applicant]
JP 2017524396A · 2017 [cited by applicant]
JP 2020505099 · 2020 [cited by applicant]
JP 2022551604 · 2022 [cited by applicant]
WO 2015109023 · 2015 [cited by applicant]
WO 2017023864 · 2017 [cited by applicant]
WO 2018129351 · 2018 [cited by applicant]
WO 2021067751 · 2021 [cited by applicant]
“International Application Serial No. PCT US2018 012631, Invitation to Pay Add'l Fees and Partial Search Report mailed Mar. 27, 2018”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT US2018 012631, International Search Report mailed May 30, 2018”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT US2018 012631, Written Opinion mailed May 30, 2018”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/196,863, Notice of Allowance mailed Feb. 20, 2019”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT US2018 012631, International Preliminary Report on Patentability mailed Jul. 18, 2019”, 10 pgs. [cited by applicant]
“Chinese Application Serial No. 201880012637.9, Notification to Make Rectification mailed Sep. 10, 2019”, w o English Translation, 1 pg. [cited by applicant]
“U.S. Appl. No. 16/416,330, Preliminary Amendment filed Dec. 26, 2019”, 8 pgs. [cited by applicant]
“European Application Serial No. 18736570.5, Extended European Search Report mailed Sep. 30, 2020”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT US2020 054006, International Search Report mailed Dec. 21, 2020”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT US2020 054006, Written Opinion mailed Dec. 21, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, Non Final Office Action mailed Jan. 7, 2021”, 11 pgs. [cited by applicant]
“Personalized medicine”, https: web.archive.org web 20190417064230 https: www.nature.com subjectspersonalized-medicine, (Apr. 17, 2019), 5 pgs. [cited by applicant]
“National Institutes of Health”, https: web.archive.org web 20190829044030 https: allofus.nih.gov , (Aug. 29, 2019), 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, Response filed Apr. 7, 2021 to Non Final Office Action mailed Jan. 7, 2021”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/416,330, Non Final Office Action mailed Apr. 14, 2021”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, Notice of Allowance mailed Apr. 23, 2021”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, PTO Response to Rule 312 Communication mailed May 20, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/241,924, Non Final Office Action mailed Jul. 12, 2021”. [cited by applicant]
“U.S. Appl. No. 17/241,924, Response filed Oct. 12, 2021 to Non Final Office Action mailed Jul. 12, 2021”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 17/241,924, Notice of Allowance mailed Oct. 28, 2021”, 5 pgs. [cited by applicant]
Allen, R P, “Restless Legs Syndrome Willis-Eckbom Disease Pathophysiology”, Sleep Med Clin. , 10(3), (2015), 207-214. [cited by applicant]
Clemens, S, “Restless leg syndrome: revisiting the dopamine hypothesis from the spinal cord perspective”, Neurology, 67, (2006), 7 pgs. [cited by applicant]
Hayashibe, Mitsuhiro, “Evoked Electromyographically Controlled Electrical Stimulation”, Frontiers in Neuroscience, (Jul. 14, 2016), 7 pgs. [cited by applicant]
Kilgore, K. L, “Nerve conduction block utilising high-frequency alternating current.”, Med Biol Eng Comput., 42(3), (May 2004), 394-406. [cited by applicant]
Mitchell, U, “Medical devices for restless leg syndrome—clinical utility of the Relaxis pad”, Ther and Clin Risk Management, (2015), 1789-1794. [cited by applicant]
Qing, K, “Burst-Modulated Waveforms Optimize Electrical Stimuli for Charge Efficiency and Fiber Selectivity”, IEEE Trans Neural Syst Rehabil Eng 23(6), (Nov. 2015), pp. 936-945. [cited by applicant]
Schoen, Nathan, “The Use of Intraoperative Electromyogram During Spinal Cord Stimulator Placement Surgery: A Case Series”, World Neurosurgery vol. 100, (Apr. 2017), pp. 74-84. [cited by applicant]
Stewart, W, “Prevalence and burden of overactive bladder in the United States”, World J Urol, 20 327-336, (2003), 11 pgs. [cited by applicant]
Vance, Carol GT, “Using TENS for pain control: the state of the evidence”, Pain Management 4(3), 197-209, (2014), 13 pgs. [cited by applicant]
“European Application Serial No. 20793537.0, Response to Communication pursuant to Rules 161(1) and 162 EPC Response filed Nov. 23, 2022”, 41 pgs. [cited by applicant]
“U.S. Appl. No. 17/583,990, Preliminary Amendment filed Apr. 4, 2022”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT US2020 054006, International Preliminary Report on Patentability mailed Apr. 14, 2022”, 10 pgs. [cited by applicant]
“Chinese Application Serial No. 202080078972.6, Notification to Make Rectification mailed Jun. 16, 2022”, w o English Translation, 1 pg. [cited by applicant]
U.S. Appl. No. 16/196,863 U.S. Pat. No. 10,342,977, filed Nov. 20, 2018, Restless Leg Syndrome or Overactive Nerve Treatment. [cited by applicant]
U.S. Appl. No. 17/062,010 U.S. Pat. No. 11,103,691, filed Oct. 2, 2020, Peripheral Nerve Stimulation for Restless Legs Syndrom. [cited by applicant]
U.S. Appl. No. 17/241,924, filed Apr. 27, 2021, Variable Operating Point Neural Electrostimulation Such as to Treat RLS. [cited by applicant]
“Japanese Application Serial No. 2022-520538, Notification of Reasons for Refusal mailed Apr. 30, 2024”, w/ English translation, 14 pgs. [cited by applicant]
“U.S. Appl. No. 17/583,990, Non Final Office Action mailed Aug. 28, 2024”, 10 pgs. [cited by applicant]